Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm Taiwan's EBIT per Share for the
three
months ended in Dec. 2025 was NT$0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.20.
During the past 12 months, the average EBIT per Share Growth Rate of Scinopharm Taiwan was -66.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -35.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -16.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -13.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Scinopharm Taiwan's EBIT per Share or its related term are showing as below:
TPE:1789'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -35.6 Med: -10.9 Max: 15
Current: -35.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Scinopharm Taiwan was 15.00% per year. The lowest was -35.60% per year. And the median was -10.90% per year.
TPE:1789's 3-Year EBIT Growth Rate is ranked worse than 91.74% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs TPE:1789: -35.60
Scinopharm Taiwan (TPE:1789) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Scinopharm Taiwan EBIT per Share Related Terms
Scinopharm Taiwan EBIT per Share Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a EBIT per Share of NT$0.20 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Scinopharm Taiwan and its competitors. According to the industry distribution chart, Scinopharm Taiwan ranks #744 out of 811 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is Scinopharm Taiwan's EBIT per Share too high?
Scinopharm Taiwan's current EBIT per Share is NT$0.20. Based on the distribution chart, Scinopharm Taiwan ranks #744 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scinopharm Taiwan has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #744 out of 811 companies for EBIT per Share. This places Scinopharm Taiwan in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current EBIT per Share is NT$0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.33, compared to a current price of NT$19.90 — trading 27.2% below its estimated fair value. The current EBIT per Share is NT$0.20. Scinopharm Taiwan's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current EBIT per Share is NT$0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.90 is trading 27.2% below its estimated GF Value™ of NT$27.33.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
EBIT per Share: NT$0.20
GF Value™: NT$27.33 vs. price of NT$19.90 (27.2% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
73GF Score
Get the complete analysis for TPE:1789
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
